← Every company

Agios Pharmaceuticals Inc Lobbying

What Agios Pharmaceuticals Inc discloses spending to lobby Congress, and who it pays to do it. Every lobbying firm files quarterly under the Lobbying Disclosure Act, naming its client, its fee and the issues it worked.

AGIO on carbonthat →
Disclosed spend
$130K
across every filing on file
Filings
6
Years covered
1
Firms retained
3

What it lobbies about

Health IssuesMedical/Disease Research/Clinical LabsMedicare/Medicaid

6 filings

Newest year first, and within a year the largest fee first — a filing period is a word rather than a date, so it cannot order itself.

PeriodLobbying for themDisclosed
20261st Quarter (Jan 1 - Mar 31)AGIOS PHARMACEUTICALSHealth IssuesMedical/Disease Research/Clinical Labs$70K
20262nd Quarter (Apr 1 - June 30)AGIOS PHARMACEUTICALSHealth IssuesMedical/Disease Research/Clinical Labs$30K
20262nd Quarter (Apr 1 - June 30)JEFFREY J. KIMBELL & ASSOCIATES, INC.Health Issues$10K
20261st Quarter (Jan 1 - Mar 31)JEFFREY J. KIMBELL & ASSOCIATES, INC.Health Issues$10K
20262nd Quarter (Apr 1 - June 30)GRIDIRON PUBLIC AFFAIRS, LLCHealth Issues$10K
20262nd Quarter (Apr 1 - June 30)GRIDIRON PUBLIC AFFAIRS, LLCHealth Issues—

A filing reports either the fee paid to a lobbying firm or what a company spent lobbying for itself, never both, so the total is a sum of the two. The client is named as filed, which is often a subsidiary. Lobbying is lawful, disclosed and extremely common — the figure is context, not an accusation.

More on AGIO

Related datasets